Bretylium
Back to searchMolecule Structure
Scientific Name
Bretylium
Description of the Drug
Bretylium is a norepinephrine release inhibitor used for the prophylaxis and therapy of ventricular fibrillation, as well as the treatment of life-threatening ventricular arrhythmias.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01158
http://www.drugbank.ca/drugs/DB01158
Brand Name(s)
Not Available
Company Owner(s)
Luitpold Pharmaceuticals Inc, Breckenridge Pharmaceutical Inc, International Medication System, Hospira Inc, Abbott Laboratories Pharmaceutical Products Div, Abraxis Pharmaceutical Products, B Braun Medical Inc, Hospira Worldwide, Inc, Hikma Pharmaceuticals Usa Inc, Astrazeneca Lp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Norepinephrine transporter | SINGLE PROTEIN | SUBSTRATE | CHEMBL222 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL15438 | |
| PharmGKB | PA448662 | |
| Human Metabolome Database | HMDB0015289 | |
| DrugBank | DB01158 | |
| PubChem: Thomson Pharma | 14749639 | |
| PubChem | 2431 | |
| LINCS | LSM-5607 | |
| Nikkaji | J4.602G | |
| BindingDB | 50239966 | |
| EPA CompTox Dashboard | DTXSID3046958 | |
| DrugCentral | 394 | |
| ChemicalBook | CB31178143 | |
| Guide to Pharmacology | 7130 | |
| rxnorm | BRETYLIUM TOSYLATE | BRETYLIUM |
| KEGG Ligand | C06855 | |
| ChEBI | 3172 | |
| ZINC | ZINC000000001041 |
